There is much to be learnt about the costs of multiple sclerosis in Latin America

There is much to be learnt about the costs of multiple sclerosis in Latin America

METHOD: A systematic review of the literature from 1990 to 2011 was conducted. Outcome measures included: mean cost of disease modifying therapies (DMTs), mean cost of treatment of relapses and mean cost of disease by stage stratification measured by the expanded disability status sc...

Full description

Bibliographic Details
Main Authors: Marina Romano, Gerardo Machnicki, Juan Ignacio Rojas, Nadina Frider, Jorge Correale
Format: Article
Language:English
Published: Academia Brasileira de Neurologia (ABNEURO) 2013-08-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
esclerosis multiple
America Latina
costos
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000800549&lng=en&tlng=en
id doaj-89f4a5cf56a64a82bac879958ce67e4e
record_format Article
spelling doaj-89f4a5cf56a64a82bac879958ce67e4e2020-11-25T00:31:57ZengAcademia Brasileira de Neurologia (ABNEURO)Arquivos de Neuro-Psiquiatria1678-42272013-08-0171854955510.1590/0004-282X20130082S0004-282X2013000800549There is much to be learnt about the costs of multiple sclerosis in Latin AmericaMarina RomanoGerardo MachnickiJuan Ignacio RojasNadina FriderJorge CorrealeMETHOD: A systematic review of the literature from 1990 to 2011 was conducted. Outcome measures included: mean cost of disease modifying therapies (DMTs), mean cost of treatment of relapses and mean cost of disease by stage stratification measured by the expanded disability status scale (EDSS). RESULTS: Seven studies from three countries (Brazil, Argentina and Colombia) were included. In 2004, in Argentina, the mean cost of DMT treatment was reported to be USD 35,000 per patient treated. In Brazil, the total MS expenditure of DMTs rose from USD 14,011,700 in 2006 to USD 122,575,000 in 2009. Patient costs ranged between USD 10,543 (EDSS 8-9.5) and USD 25,713 (EDSS 3-5.5). Indirect costs markedly increased for the EDSS 8-9.5 patients. CONCLUSION: Further research assessing the economic burden of MS in LA is warranted.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000800549&lng=en&tlng=enesclerosis multipleAmerica Latinacostos
collection DOAJ
language English
format Article
sources DOAJ
author Marina Romano
Gerardo Machnicki
Juan Ignacio Rojas
Nadina Frider
Jorge Correale
spellingShingle Marina Romano
Gerardo Machnicki
Juan Ignacio Rojas
Nadina Frider
Jorge Correale
There is much to be learnt about the costs of multiple sclerosis in Latin America
Arquivos de Neuro-Psiquiatria
esclerosis multiple
America Latina
costos
author_facet Marina Romano
Gerardo Machnicki
Juan Ignacio Rojas
Nadina Frider
Jorge Correale
author_sort Marina Romano
title There is much to be learnt about the costs of multiple sclerosis in Latin America
title_short There is much to be learnt about the costs of multiple sclerosis in Latin America
title_full There is much to be learnt about the costs of multiple sclerosis in Latin America
title_fullStr There is much to be learnt about the costs of multiple sclerosis in Latin America
title_full_unstemmed There is much to be learnt about the costs of multiple sclerosis in Latin America
title_sort there is much to be learnt about the costs of multiple sclerosis in latin america
publisher Academia Brasileira de Neurologia (ABNEURO)
series Arquivos de Neuro-Psiquiatria
issn 1678-4227
publishDate 2013-08-01
description METHOD: A systematic review of the literature from 1990 to 2011 was conducted. Outcome measures included: mean cost of disease modifying therapies (DMTs), mean cost of treatment of relapses and mean cost of disease by stage stratification measured by the expanded disability status scale (EDSS). RESULTS: Seven studies from three countries (Brazil, Argentina and Colombia) were included. In 2004, in Argentina, the mean cost of DMT treatment was reported to be USD 35,000 per patient treated. In Brazil, the total MS expenditure of DMTs rose from USD 14,011,700 in 2006 to USD 122,575,000 in 2009. Patient costs ranged between USD 10,543 (EDSS 8-9.5) and USD 25,713 (EDSS 3-5.5). Indirect costs markedly increased for the EDSS 8-9.5 patients. CONCLUSION: Further research assessing the economic burden of MS in LA is warranted.
topic esclerosis multiple
America Latina
costos
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000800549&lng=en&tlng=en
work_keys_str_mv AT marinaromano thereismuchtobelearntaboutthecostsofmultiplesclerosisinlatinamerica
AT gerardomachnicki thereismuchtobelearntaboutthecostsofmultiplesclerosisinlatinamerica
AT juanignaciorojas thereismuchtobelearntaboutthecostsofmultiplesclerosisinlatinamerica
AT nadinafrider thereismuchtobelearntaboutthecostsofmultiplesclerosisinlatinamerica
AT jorgecorreale thereismuchtobelearntaboutthecostsofmultiplesclerosisinlatinamerica
_version_ 1725321645312180224

Similar Items